ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence
JAMA Dermatology · 01.09.2026 · 162 (9) · 880
DOI: 10.1001/jamadermatol.2026.2153 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Dermatology, erschienen am 01.09.2026. Verfasst von Manisha Thakuria und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Antibodies, Viral, Carcinoma, Merkel Cell, Circulating Tumor DNA, Merkel cell polyomavirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Merkel cell carcinoma (MCC) is associated with a high recurrence rate of 40%. It is important to know which of 2 blood-based tumor biomarkers available for use in clinical practice is more accurate in detecting MCC recurrence.
Objective
To compare the performance of circulating tumor DNA (ctDNA) and the MCC polyomavirus (MCPyV) oncoprotein antibody test for detecting MCC recurrence. Design, Setting, and Participants In this multicenter cohort study across 3 US academic centers (Stanford, Dana-Farber Brigham, and University of Washington), patients with stage I-IV MCC underwent serial paired ctDNA and antibody testing for disease surveillance between April 2020 and March 2024. ctDNA was considered positive if mean tumor molecules per milliliter of plasma values were greater than 0.00, while a rising antibody test result was defined as a 30% or greater increase in titer. Inclusion criteria were clinically disease-free at baseline, detectable MCPyV antibodies at diagnosis, and both ctDNA and antibody tests performed within 45 days of each other in at least 1 time point per patient. Predictive performance for recurrence was assessed and compared between tests. Main Outcomes and Measures The primary outcome was clinical recurrence. Predictive performance measures for each test included positive (PPV), negative predictive value (NPV), and hazard ratios (HRs).
Results
In this study among 169 patients with 703 paired tests (median testing interval, 96 days; 109 males [64%]; 60 females [36%]), there were 36 clinical recurrences from 32 patients over a median follow-up of 483 days (IQR, 274-714 days). Compared with antibody testing, ctDNA had a significantly higher PPV at 365 days (73% [95% CI, 58%-85%] vs 52% [95% CI, 32%-71%]; P = .02), higher NPV at 90 days (99% [95% CI, 98.8%-100%] vs 97% [95% CI, 95%-98%]; P = .001), and a greater HR (HR, 47.9 [95% CI, 16.5-139.0] vs 7.3 [95% CI, 3.8-13.9]; HR ratio, 6.6 [95% CI, 2.5-41.0]; P < .001). Use of both ctDNA and antibody tests together identified only 1 additional recurrence compared with the use of ctDNA testing alone. Conclusions and Relevance This study found that ctDNA was more accurate than MCPyV antibody testing in detecting recurrence of MCC. ctDNA appears to be a more reliable guide than the MCPyV antibody for surveillance practices and ongoing risk stratification in most patients with MCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
- Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
- Department of Dermatology, University of Washington, Seattle.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
- Albert Einstein College of Medicine, Bronx, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Thakuria, M., Akaike, T., Silk, A. W., Hippe, D. S., Ch'en, P. Y., Alam, R., Chan, J. E., Park, S. Y., Khaddour, K., Biese, K. B., Jabbour, A. J., Fu, A., Gilmour, M. W., Finberg, A., Chiu, M. W., Kim, H., Urman, N. M., Hall, E. T., Bhatia, S., …, & Zaba, L. C. (2026). ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence. JAMA Dermatology, 162(9), 880. https://doi.org/10.1001/jamadermatol.2026.2153
Vancouver
Thakuria M, Akaike T, Silk AW, Hippe DS, Ch'en PY, Alam R, et al. ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence. JAMA Dermatology. 2026;162(9):880. doi:10.1001/jamadermatol.2026.2153
BibTeX
@article{Thakuria2026,
author = {Thakuria, Manisha and Akaike, Tomoko and Silk, Ann W and Hippe, Daniel S and Ch'en, Peter Y and Alam, Rian and Chan, Joshua E and Park, Song Y and Khaddour, Karam and Biese, Kate B and Jabbour, Austin J and Fu, Alex and Gilmour, Macy W and Finberg, Ariel and Chiu, Meliea W and Kim, Hannah and Urman, Nicole M and Hall, Evan Thomas and Bhatia, Shailender and Nghiem, Paul and Zaba, Lisa C},
title = {ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence},
journal = {JAMA Dermatology},
year = {2026},
volume = {162},
number = {9},
pages = {880},
doi = {10.1001/jamadermatol.2026.2153}
}
EUVIMED